Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 1:2021:20-0196.
doi: 10.1530/EDM-20-0196. Online ahead of print.

Breast cancer in multiple endocrine neoplasia type 1 (MEN1)

Affiliations

Breast cancer in multiple endocrine neoplasia type 1 (MEN1)

Seong Keat Cheah et al. Endocrinol Diabetes Metab Case Rep. .

Abstract

Summary: A 38-year-old female was identified as carrying a heterozygous pathogenic MEN1 variant (c.1304delG) through predictive genetic testing, following a diagnosis of familial hyperparathyroidism. Routine screening for parathyroid and pituitary disease was negative. However, cross-sectional imaging by CT revealed a 41 mm pancreatic tail mass. Biopsy via endoscopic ultrasound confirmed the lesion to be a well-differentiated (grade 1) pancreatic neuroendocrine tumour (pNET) with MIB1<1%. Biochemically, hyperinsulinaemic hypoglycaemia was confirmed following an overnight fast, which was subsequently managed by diet alone prior to definitive surgery. Pre-operative work-up with octreotide SPECT CT demonstrated avid tracer uptake in the pancreatic lesion and, unexpectedly, a focal area of uptake in the left breast. Further investigation, and subsequent mastectomy, confirmed ductal carcinoma in situ pT2 (23 mm) grade 1, N0 (ER positive; HER2 negative). Following mastectomy, our patient underwent a successful distal pancreatectomy to resect the pNET. Loss of heterozygosity (LOH) at the MEN1 locus was found in both the breast tumour and pNET, thereby in keeping with a 'two-hit' hypothesis of oncogenesis, a suggestive but non-definitive clue for causation. To obtain further support for a causative relationship between MEN1 and breast cancer, we undertook a detailed review of the published literature which overall supports the notion that breast cancer is a MEN1-related malignancy that presents at a younger age and histologically, is typically of ductal subtype. Currently, clinical guidance regarding breast cancer surveillance in MEN1 does not exist and further research is required to establish a clinical and cost-effective surveillance strategy).

Learning points: We describe a case of pNET and breast cancer diagnosed at a young age of 38 years in a patient who is heterozygous for a pathogenic MEN1 variant. Loss of the wild-type allele was seen in both breast tissue and pNET specimen. Breast cancer may be an under-recognised MEN1-associated malignancy that presents at a younger age than in the general population with a relative risk of 2-3. Further research is required to determine the cost-effectiveness of breast cancer surveillance approach at a younger age in MEN1 patients relative to the general population .

PubMed Disclaimer

Figures

Figure 1
Figure 1
Family tree with background familial hyperparathyroidism.
Figure 2
Figure 2
(A) Cross-sectional CT revealed a 41 × 29 mm heterogeneous mass in the tail of the pancreas. (B) Octreotide SPECT CT showing avid uptake in the pancreatic mass. (C) Octreotide SPECT CT showing avid uptake in the left breast (lower panel, yellow arrow).

References

    1. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA. et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997. 276 404–407. (10.1126/science.276.5311.404) - DOI - PubMed
    1. Rizzoli R, Green J, Marx SJ.Primary hyperparathyroidism in familial multiple endocrine neoplasia type I. Long-term follow-up of serum calcium levels after parathyroidectomy. American Journal of Medicine 1985. 78 467–4. (10.1016/0002-9343(85)90340-7) - DOI - PubMed
    1. Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, Melmed S, Sakurai A, Tonelli F, Brandi ML. et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). Journal of Clinical Endocrinology and Metabolism 2012. 97 2990–3011. (10.1210/jc.2012-1230) - DOI - PubMed
    1. van Leeuwaarde RS, Dreijerink KM, Ausems MG, Beijers HJ, Dekkers OM, de Herder WW, van der Horst-Schrivers AN, Drent ML, Bisschop PH, Havekes B. et al. MEN1-dependent breast cancer: indication for early screening? Results from the Dutch MEN1 study group. Journal of Clinical Endocrinology and Metabolism 2017. 102 2083–20. (10.1210/jc.2016-3690) - DOI - PubMed
    1. Dreijerink KMA, Goudet P, Burgess JR, Valk GD.International Breast Cancer in MEN1 Study Group. Breast-cancer predisposition in multiple endocrine neoplasia type 1. New England Journal of Medicine 2014. 371 583–58. (10.1056/NEJMc1406028) - DOI - PMC - PubMed

LinkOut - more resources